Dr Boreham's Crucible: Argenica Therapeutics
Argenica Therapeutics is aiming for a substantial slice of the stroke market, expected to be worth some US$180bn a year by 2030
Source: fnarena.com
Stay updated with breaking news from Bruno Meloni. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Argenica Therapeutics is aiming for a substantial slice of the stroke market, expected to be worth some US$180bn a year by 2030
The hours after a stroke are crucial and Perth scientists are hoping a breakthrough drug can reduce the sev...
Biotechnology company Argenica Therapeutics (ASX: AGN) has announced positive findings from an international peer-reviewed study assessing the safety of its lead drug ARG-007 to reduce brain tissue death after stroke.